Heptazyme: Phase I

In a Phase I trial of subcutaneous doses of 0.3-90 mg per patient per day over 28 days, RZYM said that Heptazyme was well tolerated at all doses (see BioCentury, Sept. 18). In a multi-dose study of 12...